While the latter shows better efficacy, the survival of mice with colon and ovarian cancer was significantly prolonged, the levels of tumor necrosis factor-α (TNF-α) (a known toxic mediator of IL-2) were reduced, the tumor-infiltrating CD8+ T cell population was increased, and the CD8+/Treg cell ratio was increased significantly. The gene discussed is CD8A; the disease is ovarian carcinoma.